Bafiertam Oral Capsules Approved by the FDA for Relapsing Forms of MS

On April 30, 2020, Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced the United States Food and Drug Administration (FDA) approval of Bafiertam™ (monomethyl fumarate) delayed-release oral capsules to treat relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Banner has not yet announced when the medication will be available to the MS community.

Read News Article

The Motivator 2019 Archives

MSAA’s magazine highlights and explains many vital issues of importance to our readers affected by MS. Columns appearing in each issue include “Ask the Doctor,” “Research News,” “Program Notes,” and […]

Read News Article